WO2021123320A1 - Composition et son utilisation pour une thérapie universelle contre les cellules tumorales - Google Patents
Composition et son utilisation pour une thérapie universelle contre les cellules tumorales Download PDFInfo
- Publication number
- WO2021123320A1 WO2021123320A1 PCT/EP2020/087239 EP2020087239W WO2021123320A1 WO 2021123320 A1 WO2021123320 A1 WO 2021123320A1 EP 2020087239 W EP2020087239 W EP 2020087239W WO 2021123320 A1 WO2021123320 A1 WO 2021123320A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- fragment
- protein
- sequence
- cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 210000004881 tumor cell Anatomy 0.000 title description 14
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000012634 fragment Substances 0.000 claims abstract description 117
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 claims abstract description 8
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 claims abstract description 8
- 108050006602 Metalloproteinase inhibitor 2 Proteins 0.000 claims abstract description 8
- 102100029529 Thrombospondin-2 Human genes 0.000 claims abstract description 8
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims abstract description 8
- 108010060887 thrombospondin 2 Proteins 0.000 claims abstract description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 202
- 206010028980 Neoplasm Diseases 0.000 claims description 138
- 108090000623 proteins and genes Proteins 0.000 claims description 72
- 210000002950 fibroblast Anatomy 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 239000006228 supernatant Substances 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 36
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 208000026310 Breast neoplasm Diseases 0.000 claims description 32
- 206010006187 Breast cancer Diseases 0.000 claims description 30
- 235000003642 hunger Nutrition 0.000 claims description 25
- 230000037351 starvation Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims description 8
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102100031812 Fibulin-1 Human genes 0.000 claims description 7
- 102100039440 Inter-alpha-trypsin inhibitor heavy chain H2 Human genes 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 7
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims description 7
- 102100030510 Stanniocalcin-2 Human genes 0.000 claims description 7
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 7
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims description 7
- 102100031170 CCN family member 3 Human genes 0.000 claims description 6
- 102100038083 Endosialin Human genes 0.000 claims description 6
- 101710170731 Fibulin-1 Proteins 0.000 claims description 6
- 108010001498 Galectin 1 Proteins 0.000 claims description 6
- 102100021736 Galectin-1 Human genes 0.000 claims description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 6
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims description 6
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims description 6
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 claims description 6
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 claims description 6
- 101710083919 Inter-alpha-trypsin inhibitor heavy chain H2 Proteins 0.000 claims description 6
- 102100027017 Latent-transforming growth factor beta-binding protein 2 Human genes 0.000 claims description 6
- 108050001515 Liprin-beta-2 Proteins 0.000 claims description 6
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 claims description 6
- 101710192097 Pentraxin-related protein PTX3 Proteins 0.000 claims description 6
- 101710142154 Stanniocalcin-2 Proteins 0.000 claims description 6
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 6
- 102000019316 Transgelin-2 Human genes 0.000 claims description 6
- 108050006805 Transgelin-2 Proteins 0.000 claims description 6
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 claims description 6
- 102100038910 Alpha-enolase Human genes 0.000 claims description 5
- 101710137351 CCN family member 3 Proteins 0.000 claims description 5
- 102000003908 Cathepsin D Human genes 0.000 claims description 5
- 108090000258 Cathepsin D Proteins 0.000 claims description 5
- 108010061642 Cystatin C Proteins 0.000 claims description 5
- 101710144543 Endosialin Proteins 0.000 claims description 5
- 101710163784 Growth-regulated alpha protein Proteins 0.000 claims description 5
- 101710178974 Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 claims description 5
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims description 5
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 5
- 102000010208 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 5
- 108050001894 Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims description 5
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims description 5
- 108010049777 Ankyrins Proteins 0.000 claims description 3
- 102000008102 Ankyrins Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102100031981 Liprin-beta-2 Human genes 0.000 claims description 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 101710185837 3-hydroxyacyl-thioester dehydratase Z Proteins 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims 1
- 102000019210 Metalloproteinase inhibitor 2 Human genes 0.000 abstract description 7
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 71
- 239000000243 solution Substances 0.000 description 60
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 59
- 230000014509 gene expression Effects 0.000 description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 40
- 230000000694 effects Effects 0.000 description 32
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 29
- 239000012091 fetal bovine serum Substances 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 23
- 239000002609 medium Substances 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 230000035899 viability Effects 0.000 description 22
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 20
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 19
- 206010016654 Fibrosis Diseases 0.000 description 18
- 230000004761 fibrosis Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 206010028851 Necrosis Diseases 0.000 description 17
- 230000017074 necrotic cell death Effects 0.000 description 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 16
- 229960003957 dexamethasone Drugs 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 210000001733 follicular fluid Anatomy 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 13
- 210000000497 foam cell Anatomy 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000009401 metastasis Effects 0.000 description 12
- 230000004075 alteration Effects 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 231100000002 MTT assay Toxicity 0.000 description 8
- 238000000134 MTT assay Methods 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000003979 eosinophil Anatomy 0.000 description 7
- 210000005075 mammary gland Anatomy 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 231100001274 therapeutic index Toxicity 0.000 description 7
- 102100020921 Follistatin Human genes 0.000 description 6
- -1 Nanog Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102100026897 Cystatin-C Human genes 0.000 description 5
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 108010014612 Follistatin Proteins 0.000 description 5
- 108010012820 Follistatin-Related Proteins Proteins 0.000 description 5
- 102000019203 Follistatin-Related Proteins Human genes 0.000 description 5
- 101150112014 Gapdh gene Proteins 0.000 description 5
- 102000011323 Liprin-beta-2 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 241000009328 Perro Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100030416 Stromelysin-1 Human genes 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003118 histopathologic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102100039543 Uveal autoantigen with coiled-coil domains and ankyrin repeats Human genes 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000010598 annexinV-PE /7AAD assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000005748 tumor development Effects 0.000 description 4
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 101710090735 Uveal autoantigen with coiled-coil domains and ankyrin repeats Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 231100001221 nontumorigenic Toxicity 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 2
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 101150081864 Spr gene Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- ZYXYTGQFPZEUFX-UHFFFAOYSA-N benzpyrimoxan Chemical compound O1C(OCCC1)C=1C(=NC=NC=1)OCC1=CC=C(C=C1)C(F)(F)F ZYXYTGQFPZEUFX-UHFFFAOYSA-N 0.000 description 2
- 201000007180 bile duct carcinoma Diseases 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 description 2
- 201000003714 breast lobular carcinoma Diseases 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 210000000321 buccal mucosa cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 208000024724 pineal body neoplasm Diseases 0.000 description 2
- 201000004123 pineal gland cancer Diseases 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101150036984 CCN3 gene Proteins 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100029378 Follistatin-related protein 1 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102100022191 Hemogen Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000001420 Homeobox domains Human genes 0.000 description 1
- 108050009606 Homeobox domains Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 1
- 101001065276 Homo sapiens Fibulin-1 Proteins 0.000 description 1
- 101001062535 Homo sapiens Follistatin-related protein 1 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101001045553 Homo sapiens Hemogen Proteins 0.000 description 1
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 101000840566 Homo sapiens Insulin-like growth factor-binding protein 5 Proteins 0.000 description 1
- 101000840582 Homo sapiens Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101000609396 Homo sapiens Inter-alpha-trypsin inhibitor heavy chain H2 Proteins 0.000 description 1
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 description 1
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 description 1
- 101001064427 Homo sapiens Liprin-beta-2 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 1
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
- 101000701446 Homo sapiens Stanniocalcin-2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 101000652726 Homo sapiens Transgelin-2 Proteins 0.000 description 1
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
- 101000608672 Homo sapiens Uveal autoantigen with coiled-coil domains and ankyrin repeats Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 102100029225 Insulin-like growth factor-binding protein 5 Human genes 0.000 description 1
- 102100029180 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001579016 Nanoa Species 0.000 description 1
- 108700024729 Nephroblastoma Overexpressed Proteins 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 102100031016 Transgelin-2 Human genes 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000007253 cellular alteration Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010250 in vitro experimental analysis Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000008410 smoothened signaling pathway Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
Definitions
- the present invention relates to a composition, a cell supernatant comprising the same, a pharmaceutical composition comprising the same, and a method of preparing the same.
- Tumorigenesis is a (multi) complex biological process in which different types of cells contribute in an orchestral manner (Cao, et al, 2017).
- This cellular network consists of malignant cells, endothelial cells, immune cells, and fibroblasts, among of which non-tumor cells play different roles but orchestra to angiogenesis and tumor metastasis, and fibroblasts of stromal cells play an important role in angiogenesis (cancer-associated fibroblast) (Cao et al, 2017; Kalluri, et al, 2016).
- fibroblasts In addition to collagen synthesis, fibroblasts have secretory phenotype releasing different compounds into the extracellular matrix, each of which can have important roles at all stages of cancer progression, wound healing and regeneration (Kalluri, et al, 2016). Cancer stem cells are among a few cancer cells surviving during different steps of metastasis and have high potential in initiating and promoting metastasis (Zhang et al, 2018). Moreover, serum starvation has been recently considered as a model for a biological study on tumor (Tian et al, 2017; Netherlands et al, 2017).
- Tissue specific stem cells are main stem cells in tissues hemostasis. These undifferentiated cells characterized by self-renewing, rendering them a prolonged lifespan which make these parent cells prone or susceptible to a variety set of intrinsic and extrinsic mutagenic factors transforming these cells to a special type of tumorigenic stem cells. Accumulating data show that these cells are resistance to radiotherapy and chemotherapy, causing the relapse of cancer related diseases after treatment with such current available cancer therapy.
- CSCs cancer stem cells
- Hedgehog, and Wnt signaling pathways that may be dysregulated in normal breast stem cells and consequently differentiated into CSCs (Chatterjee & Sil, 2019; Munoz, lliou, & Esteller, 2012), some transcriptional factors including octamer-binding transcription factor 4 (Oct4), sex determining region Y-box 2 (Sox2), the homeobox domain transcription factor Nanog and C-myc also play role in this differentiation (Wan, 2019; Yamanaka, 2008).
- Oct4 octamer-binding transcription factor 4
- Sox2 sex determining region Y-box 2
- Nanog sex determining region Y-box 2
- C-myc also play role in this differentiation (Wan, 2019; Yamanaka, 2008).
- Oct4 and Sox2 have a key role in maintaining and inducing pluripotency (Esch et al., 2013; Yilmaz & Benvenisty, 2019), and also contribute in tumor growth and metastasis (Munro, Wickremesekera, Peng, Tan, & Itinteang, 2018; Sarkar & Hochedlinger, 2013).
- Nanog is considered as a key regulator of embryonic development and cellular reprogramming, and takes part in self-renewal of CSCs (Das et al., 2019; Jeter, Yang, Wang, Chao, & Tang, 2015), C-myc is an oncoprotein with various roles in apoptosis, division and differentiation of cell (van Schaijik, Davis, Wickremesekera, Tan, & Itinteang, 2018). Previous studies showed that the expression of Yamanaka factors and Nanog are associated with CSCs so that the decrease in this expression leads to the differentiation of the CSCs to the cancer cells (Leis et al., 2012; Xiang et al., 2011; You, Guo, & Huang, 2018).
- Downregulation of pluripotency transcription factors can be carried out through different signaling pathways including the Wnt/ -catenin, Shh (sonic hedgehog), Notch/y-secretase/Jagged and BMP (Czerwinska and Kaminska, 2015).
- Shh sonic hedgehog
- Notch/y-secretase/Jagged BMP (Czerwinska and Kaminska, 2015).
- this suppression is carried out through DNA methylation and histone modeification in the promotor region of these genes.
- overexpression of C-myc can be replaced by Nanog and be dispensable.
- Oct4, Sox2, and Nanog are regarded as the main regulators of pluripotency. Injection of 16SFS into the tumor region causes reduction of sternness and cell growth and subsequently induces differentiation, apoptosis and necrosis.
- targeting CSCs in sense of causing apoptosis or promoting differentiation would provide an approach for treating tumors and/or cancers.
- the replicative/ functionally active cells e.g. neonatal fibroblasts or human PBMCs
- PBMCs reprogrammed their metabolism to aerobic glycolysis under serum starvation conditions (Warburg effect).
- these cells in this circumstance produce proteins which are able to induce differentiation of CSCs and cause apoptosis as well as necrosis in tumor cells and particularly in CSCs.
- the present invention provides a composition which comprises Pigment epithelium-derived factor protein having a sequence of SEQ ID NO: 1 or a fragment thereof, Thrombospondin-2 protein having a sequence of SEQ ID NO: 2 or a fragment thereof, and/or Metalloproteinase inhibitor 2 protein having a sequence of SEQ ID NO: 3 or a fragment thereof, and/or Insulin-like growth factor-binding protein 4 having a sequence of SEQ ID NO: 4 or a fragment thereof.
- Said composition can be obtained under certain starvation condition which acts against tumor cells especially CSCs.
- said composition further comprises Uveal autoantigen protein with coiled-coil domains and ankyrin repeats having a sequence of SEQ ID NO: 5 or a fragment thereof, and/or Insulin-like growth factor-binding protein 5 having a sequence of SEQ ID NO: 6 or a fragment thereof.
- above composition or above preferred composition further comprises one or more of proteins or fragments thereof selected from a group consisting of: Stromelysin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 7 or
- Metalloproteinase inhibitor 1 protein having a sequence of SEQ ID NO: 9 or a fragment thereof, Pentraxin-related protein PTX3 having a sequence of SEQ ID NO: 10 or a fragment thereof, Cathepsin D protein having a sequence of SEQ ID NO: 11 or a fragment thereof, Follistatin- related protein 1 having a sequence of SEQ ID NO: 12 or a fragment thereof, Fibulin-1 protein having a sequence of SEQ ID NO: 13 or a fragment thereof, Endosialin protein having a sequence of SEQ ID NO: 14 or a fragment thereof, Inter-alpha-trypsin inhibitor heavy chain H2 protein having a sequence of SEQ ID NO:
- SPARC protein having a sequence of SEQ ID NO: 16 or a fragment thereof,
- Growth-regulated alpha protein having a sequence of SEQ ID NO: 17 or a fragment thereof, Insulin-like growth factor-binding protein 6 having a sequence of SEQ ID NO: 18 or a fragment thereof, Protein NOV homolog having a sequence of SEQ ID NO: 19 or a fragment thereof, Follistatin protein having a sequence of SEQ ID NO: 20 or a fragment thereof, Alpha-enolase protein having a sequence of SEQ ID NO: 17 or a fragment thereof, Insulin-like growth factor-binding protein 6 having a sequence of SEQ ID NO: 18 or a fragment thereof, Protein NOV homolog having a sequence of SEQ ID NO: 19 or a fragment thereof, Follistatin protein having a sequence of SEQ ID NO: 20 or a fragment thereof, Alpha-enolase protein having a sequence of SEQ ID NO: 17 or a fragment thereof, Insulin-like growth factor-binding protein 6 having a sequence of SEQ ID NO: 18 or a fragment thereof, Protein NOV homolog having a sequence of SEQ ID
- Tumor necrosis factor-inducible gene 6 protein having a sequence of SEQ ID NO: 21 or a fragment thereof, Tumor necrosis factor-inducible gene 6 protein having a sequence of SEQ ID NO: 21 or a fragment thereof, Tumor necrosis factor-inducible gene 6 protein having a sequence of SEQ ID NO: 21 or a fragment thereof, Tumor necrosis factor-inducible gene 6 protein having a sequence of SEQ
- the composition of the present invention not only induces differentiation and down regulates the stem cell (sternness marker) but also induces apoptosis-dependent necrosis in tumor cells. Moreover, the composition of the present invention inhibits tumor cells migration (metastasis) and their growth.
- the gene expression levels of stem cell markers including Oct4, Sox2, Nanog, and C- myc in breast CSCs (LA7) were evaluated during 24 h, 72 h and 7 days of in vitro exposure to FF, P14, and 16h-SFS; with the expectation of decreasing the expression of these markers and consequently increasing the differentiation of CSCs.
- cell migration and cell growth was investigated in vitro. The in vivo effect has been investigated in Rats and ex vivo experimental proof of concept has been demonstrated using human breast cancer cells isolated from human tumors compared to healthy cells.
- the term “comprise”, “comprises” or “comprising”, should be understood as the inclusion of a stated member, integer or step but not the exclusion of any other non-stated member, integer or step.
- the term “consisting of” is a particular embodiment of the term “comprise”, indicating that any other non-stated member, integer or step is excluded.
- the term “comprise” encompasses the term “consist of”.
- the term “comprising” encompasses “including” as well as “consisting”, for example, a composition “comprising” X may consist exclusively of X or may include something additional, for example, X + Y.
- the first aspect of the present invention relates to a composition
- a composition comprising: Pigment epithelium- derived factor protein having a sequence of SEQ ID NO: 1 or a fragment thereof, Thrombospondin-2 protein having a sequence of SEQ ID NO: 2 or a fragment thereof, and/or Metalloproteinase inhibitor 2 protein having a sequence of SEQ ID NO: 3 or a fragment thereof, and/or Insulin-like growth factor binding protein 4 having a sequence of SEQ ID NO: 4 or a fragment thereof.
- the composition in the present invention comprises Pigment epithelium-derived factor protein having a sequence of SEQ ID NO: 1 or a fragment thereof, Thrombospondin-2 protein having a sequence of SEQ ID NO: 2 or a fragment thereof, Metalloproteinase inhibitor 2 protein having a sequence of SEQ ID NO: 3 or a fragment thereof, and Insulin-like growth factor-binding protein 4 having a sequence of SEQ ID NO: 4 or a fragment thereof.
- composition in the present invention disclosed above further comprises: Uveal autoantigen protein with coiled-coil domains and ankyrin repeats having a sequence of SEQ ID NO: 5 or a fragment thereof, and/or Insulin-like growth factor-binding protein 5 having a sequence of SEQ ID NO: 6 or a fragment thereof.
- composition in the present invention disclosed above further comprises one or more of proteins or fragments thereof selected from a group consisting of: Stromelysin-1 protein having a sequence of SEQ ID NO: 7 or a fragment thereof, Thrombospondin-1 protein having a sequence of SEQ ID NO: 8 or a fragment thereof, Metalloproteinase inhibitor 1 protein having a sequence of SEQ ID NO:
- Pentraxin-related protein PTX3 having a sequence of SEQ ID NO: 10 or a fragment thereof
- Cathepsin D protein having a sequence of SEQ ID NO: 11 or a fragment thereof
- Follistatin-related protein 1 having a sequence of SEQ ID NO: 12 or a fragment thereof, Fibulin-1 protein having a sequence of SEQ ID NO: 13 or a fragment thereof, Endosialin protein having a sequence of SEQ ID NO: 14 or a fragment thereof, Inter-alpha-trypsin inhibitor heavy chain H2 protein having a sequence of SEQ ID NO: 15 or a fragment thereof, SPARC protein having a sequence of SEQ ID NO: 16 or a fragment thereof, Growth-regulated alpha protein having a sequence of SEQ ID NO: 17 or a fragment thereof, Insulin-like growth factor-binding protein 6 having a sequence of SEQ ID NO: 18 or a fragment thereof, Protein NOV homolog having a sequence of SEQ ID NO: 19 or a fragment thereof, Fol listatin protein having a sequence of SEQ ID NO: 20 or a fragment thereof, Alpha-enolase protein having a sequence of SEQ ID NO: 21 or a fragment thereof, Tumor necrosis factor-inducible gene 6 protein
- fragment refers to an analogue of the corresponding protein.
- the above-disclosed fragments comprise an amino acid sequence which shows an amino acid identity of more than 70%, preferably more than 75%, more preferably more than 80% to the full-length of the corresponding protein, or shows an amino acid identity of 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to the full- length of the corresponding protein.
- fragment refers to a polypeptide comprising the one or more of the conserved domains of the corresponding protein.
- fragment refers to a polypeptide comprising at least a region which shows an amino acid identity of more than 70%, preferably more than 75%, more preferably more than 80% to one of the conserved domains of the corresponding protein, or shows an amino acid identity of 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to one of the conserved domains of the corresponding protein.
- one or more of proteins or fragments thereof included therein have an origin of vertebrate, e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, or horse cells, preferably mammal, more preferably human.
- vertebrate e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, or horse cells, preferably mammal, more preferably human.
- composition disclosed above are for use as a medicament, optionally for use in the treatment of tumor and/or cancer, further optionally for use in the treatment of breast tumor and/or cancer.
- tumors included in the present invention comprise sarcomas and carcinomas, including fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer (including basal breast carcinoma, ductal carcinoma and lobular breast carcinoma), lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma
- treatment refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
- the antibodies of the disclosure may be used to delay development of a disease or disorder or to slow the progression of a disease or disorder.
- treating refers to improving, alleviating, and/or decreasing the severity of one or more symptoms of a condition being treated.
- treating cancer refers to improving the patient's condition, alleviating, delaying or slowing progression or onset, decreasing the severity of one or more symptoms of cancer.
- treating cancer includes any one or more of: decreasing tumor size, decreasing rate of tumor size increase, halting increase in size, decreasing the number of metastases, decreasing pain, increasing survival, and increasing progression free survival.
- a therapeutically effective amount of the above-disclosed composition may be administered orally or non-orally e.g. by injection to a subject or a patient.
- Oral administration includes but is not limited to: topical administration, or parenteral administration, or combinations thereof.
- Administration by injection includes but is not limited to: via the intramuscular or intraperitoneal route, or the composition of the present invention can be injected directly into the target tumor.
- a "subject”, “individual” or “patient” may be a vertebrate, such as a human. The vertebrate may be a mammal.
- a “therapeutically effective amount” of the composition in the present invention is variable according to factors such as age, sex, the disease state, weight of the subject, and the ability of the substance/molecule, to elicit a desired response in the subject.
- a therapeutically effective amount may encompass an amount in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects.
- the second aspect of the present invention relates to a cell supernatant comprising the composition disclosed above.
- the cells from which the supernatant is derived in the present invention can be primary cells or secondary cells.
- the cells from which the supernatant is derived in the present invention may include but not be limited to: keratinocytes, fibroblasts, adipocytes, epithelial cells (including but not limited to: intestinal epithelial cells, mammary epithelial cells), neural cells, glial cells, endothelial cells, muscle cells, hepatocytes, buccal mucosa cells, hepatic cells, blood cells and immune cells (including but not limited to: bone marrow cells, cells in mononuclear cord blood, and peripheral blood mononuclear cells including lymphocytes, T-cells, B-Cells, and NK cells), stem cells including induced pluripotent stem cells (iPS cells), precursors of these cell types, or even HeLa, MCF-7, or other cancer cells.
- epithelial cells including but not limited to: intestinal epithelial cells, mammary epithelial cells
- neural cells including but not limited to: intestinal epithelial cells, mammary epitheli
- the cells from which the supernatant is derived in the present invention preferably has an origin of vertebrate, e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, horse, preferably mammal, more preferably human.
- vertebrate e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, horse, preferably mammal, more preferably human.
- the cells from which the supernatant is derived in the present invention can be primary cells isolated from a vertebrate, e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, horse, preferably from a mammal, more preferably from a human, or can be secondary cells derived from said primary cells
- the cells from which the supernatant is derived in the present invention are fibroblast cells, more preferably are human neonatal fibroblast cells.
- the cells from which the supernatant is derived in the present invention are peripheral blood mononuclear cells, more preferably are lymphocytes, even more preferably are human lymphocytes.
- the supernatant of the present invention is obtained after the cell undergoes a starvation treatment.
- the time period for starvation can be 8-112 hours, preferably 16-96 hours, more preferably 24-88 hours, even more preferably 32, 40, 48, 56, 64, 72, 80 or 104 hours.
- the inventors found that the starvation time is correlated with the desired effects of the present invention, and a starvation period of 16-96 hours is connected with a remarkable anti-cancer effect of the cell supernatant.
- the cells can be sub-cultured for 2 to 20 times, preferably 3 to 18 times, or 4-18 times, more preferably 3 to 16 times, or 6-16 times, even more preferably 3 to 5 times, and also can be 8-14 times, or 9, 10, 11, 12, 13, or 15 times.
- the time of said sub-culture can be determined by investigating the growth speed of cells. The inventors found that once the growth speed of cells is significantly slowed down, then the cells are ready for undergoing starvation treatment. The times of sub-culture is also correlated with the desired effects of the present invention. The inventors found that with 3 to 5 times of passage, the anti-cancer effect of the cell supernatant is even better.
- the cell supernatant of the present invention can be used as a medicament.
- the cell supernatant of the present invention is for use in the treatment of tumor and/or cancer, including (but not limited thereto) sarcomas and carcinomas, including fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer (including basal breast carcinoma, ductal carcinoma and lobular breast carcinoma), lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocar
- the cell supernatant in the present invention is for use in the treatment of breast tumor and/or cancer.
- the third aspect of the present invention is to provide a pharmaceutical composition comprising the composition disclosed above, or the cell supernatant disclosed above.
- the pharmaceutical composition in the present invention contains pharmaceutically acceptable carriers and/or excipients including but not being limited to: stabilizing agents, surface-active agents, salts, buffers, coloring agents etc.
- the pharmaceutical composition in the present invention is in the form of a kit of parts.
- the pharmaceutical composition of the present invention can be for use in the treatment of tumor and/or cancer which can be selected from the list disclosed above with regard to the composition for use or the cell supernatant for use.
- the pharmaceutical composition is for use in the treatment of breast tumor and/or cancer.
- the fourth aspect of the present invention is to provide an ex vivo method of preparing the composition of the present invention, comprising starving cells in culture for a determined time period, wherein said composition is contained in the cell supernatant after said starvation treatment.
- the cells can be primary cells or secondary cells.
- the cells may include but not be limited to: keratinocytes, fibroblasts, adipocytes, epithelial cells (including but not limited to: intestinal epithelial cells, mammary epithelial cells), neural cells, glial cells, endothelial cells, muscle cells, hepatocytes, buccal mucosa cells, hepatic cells, blood cells (including but not limited to: lymphocytes, bone marrow cells, cells in mononuclear cord blood, peripheral blood mononuclear cells), immune cells (including but not limited to: T-cells, B-Cells), stem cells including induced pluripotent stem cells (iPS cells), or precursors of these cell types.
- epithelial cells including but not limited to: intestinal epithelial cells, mammary epithelial cells
- neural cells including but not limited to: intestinal epithelial cells, mammary epithelial cells
- glial cells including endothelial cells
- muscle cells glial cells
- the cells preferably have an origin from a vertebrate, e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, horse, preferably from a mammal, more preferably from a human.
- the cells can be primary cells isolated from a vertebrate, e.g. human, nonhuman primates, rabbit, mouse, rat, cow, bird, sheep, goat, cat, dog, pig, horse, preferably from a mammal, more preferably from a human, or can be secondary cells derived from said primary cells.
- the cells are fibroblast cells, more preferably are human neonatal fibroblast cells.
- the time period can be 8-112 hours, preferably 16-96 hours, more preferably 24-88 hours, even more preferably 32, 40, 48, 56, 64, 72, 80 or 104 hours.
- the cells Before undergoing starvation treatment, the cells can be sub-cultured for 2 to 20 times, preferably 4 to 18 times, more preferably 6 to 16 times, even more preferably 3 to 5 times, and also can be , 8 to 14 times, 9, 10, 11, 12, 13, or 15 times.
- the time of said sub-culture can be determined by investigating the growth speed of cells. The inventors found that once the growth speed of cells is significantly slowed down, then the cells are ready for undergoing starvation treatment. The times of sub-culture is also correlated with the desired effects of the present invention. The inventors found that with 8 to 14 times of passage, the anti-cancer effect of the cell supernatant is good. In this regard, the inventors found that with 3 to 5 times of passage, the anti-cancer effect of the cell supernatant is even better.
- the fifth aspect of the present invention is to provide a cell supernatant obtained by the above disclosed ex vivo method.
- Fig. 1 Morphology of fibroblasts in passages 3 (a) and 14 (b). Compared to fibroblasts at passage 3, the fibroblasts at passage 14 exhibited some morphological changes such as enlarged cytoplasm with increased levels of granules. Moreover, the nucleus appeared more obviously, together indicated that the cells entered to senescent phase based on the previous study (Lipetz & Cristofalo, 1972). Magnification: 100X and 200X for photomicrographs (a) and (b) respectively.
- Fig. 2 Cytotoxicity evaluation of the three biological fluids including 16h-starved fibroblasts supernatant (16h-SFS), senescent fibroblast fluid (P14) and ovarian follicular fluid (FF) on LA7 cell line using MTT assay after 24 h (A), 48 h (B) and 72 h (C). These fluids were diluted in DMEM before treatment. The dilution factors were 1/1, 1/2, 1/4, 1/8, 1/16 and 1/32 Data are shown as mean ⁇ SD (three replicates). *: indicates P ⁇ 0.05 and, ***: indicates P ⁇ 0.001. P ⁇ 0.05 was considered as significant level statistically.
- Fig. 3 Doubling time alterations in LA7 treated for 72 h with control medium and three biological fluids. All fluids increased the LA7 doubling time value significantly. ***: indicates P ⁇ 0.001. Cont; control (medium + 10% FBS), 16h-SFS; 16h starved fibroblasts culture supernatant, P14; supernatant of fibroblasts at passage 14, FF; ovarian follicular fluid.
- Fig. 4 LA7 acridine orange / ethidium bromide staining.
- the cells were treated for 24 h with; A and Al) control medium (DMEM+10%FBS), B and Bl) FF (ovarian follicular fluid), C and Cl) P14 (fibroblasts culture supernatant at passage 14), D and Dl) 16h-SFS (16 h starved fibroblasts culture supernatant).
- A- D are LA7 cells before staining and Al-Dl are those cells after staining. All treated cells exhibited some degrees of both apoptosis and necrosis. Magnification; 200 X for A-D and 100X for Al-Dl.
- Fig. 5 Annexin V-PE/7-AAD staining and flow cytometry analysis.
- A) Forward scatter -height (FSC-H) and side scatter-height (SSC-H) of LA7 cells and the gated cells.
- DMEM+10%FBS control medium
- P14 fibroblasts culture supernatant at passage 14
- FF ovarian follicular fluid
- 16h-SFS (16 h starved fibroblasts culture supernatant
- Fig. 6 LA7 scratch test results. Analysis of the migration potential in LA7 cells exposed to the three biological fluids in time 0, 24 h and 48 h. C; control (medium + 10% FBS), FF; ovarian follicular fluid, P14; supernatant of fibroblast at passage 14, 16h-SFS;16 h starved fibroblasts culture supernatant, all indicated fluids were able to suppress the cells migration after 48 h. Magnification:40X.
- Fig. 7 Expression of C-myc, Nanog, Oct4, and Sox2 in LA7 cells exposed to 16h-SFS with dilutions of 1, 1/16 and 1/32 for 24 h, 72h and 7 days. *: indicates p ⁇ 0.05.
- Fig. 8 Expression of C-myc, Nanog, Oct4, and Sox2 in LA7 cells exposed to senescent fibroblast fluid with dilutions 1, 1/8, and 1/16 for 24 h, 72 h and 7 days of exposure. *: indicates p ⁇ 0.05.
- Fig. 9 Expression of C-myc, Nanog, Oct4, and Sox2 in LA7 cells exposed to FF with dilutions 1, 1/2 and 1/16 for 24h, 72h and 7 days of exposure. *: indicates p ⁇ 0.05.
- Fig. 10 Viability of MCF10A and MCF7 cells.
- Tumorigenic and non-tumorigenic human breast cell lines (MCF7 and MCF10A) were cultured to a confluency of around 80%. Subsequently, cells were treated with medium, 16SFS and 16SFS complemented with FCS. MTT assay was performed to analyze the effect of treatment on viability of the cells.
- Fig. 11 Tumors size and animals weight in test and control groups (a) The volume of tumor after injection of LA7 and different solutions, (b) Alteration of rat's weight between three groups after injection of LA7 and different solutions. The different letters show significant difference between groups (p ⁇ 0.05).
- Fig. 12 Tumors X-ray imaging. Alteration in the volume of tumors was confirmed by X-ray images, a) Normal saline group, b) DMEM group c) 16h-SFS group. Maximum size was measured in DMEM and minimum size in 16h-SFS groups.
- Fig. 13 Flistology of breast cancer in rats, a): Low mitosis (arrow), b) High mitosis (arrow), c) Low vascularity (arrow), d) High vascularity (arrow), e) Monomorphic nuclear cells (MNs). f) Polymorphic nuclear cells (PMNSs) (arrow), g) Necrosis (arrow). The magnification of a-d and g is x400 and e-f is xlOOO. H& E staining was used.
- Fig. 14 Histology of breast cancer in rat. a): Cytokeratin positive, b) Estrogen receptor- negative (arrow), c) Mast cells. The magnification of a-b is x400 and c is xlOOO. Immunohistochemical staining was used in images of a-b and Giemsa staining used in image of c.
- Fig. 15 Effects of different solutions on angiogenesis and mitosis in LA7 induced tumors
- HPF High-power field.
- Fig. 16 Alterations in the expression of Nanog, C-myc, Oct-4, and Sox2 in the breast tumors from rat exposed to normal saline or DMEM or 16h-SFS. Different letters show significant difference in each group (P ⁇ 0.05).
- Fig. 17 Alterations in the rat weight in different groups at the first day of experiment to the 60th day. Apart from 8th day, the weights of rats increased significantly. Data are shown as meaniSD.
- Fig. 18 Histopathology of the intestine stained with H&E in the different groups, (a) (Normal saline): EP (Epithelium), LG (Lieberkuhn's gland), M (muscle), SM (submucosal), (b) (Normal saline + LA7): EL (epithelium loss),), (c) (DMEM): EL (epithelium loss), (H (villous edema), (d) (LA7+DMEM):, EL (epithelium loss), H (villous edema), (e) (LA7+16SFS):, loss of villi, (f) (16h-SFS): EL (epithelium loss), H (villious edema, Scale: 2oo pm, x29. The most abundant of damages was observed in 16h- SFS group.
- Fig. 19 The average length of intestinal villi in different groups measured by Motic images Plus 2.0 ML. The most abundant change in the length of villi compared to normal saline group was observed in normal saline + LA7 group. Data are shown as mean ⁇ SD.
- Fig. 20 Histopathology of the liver stained with H&E and Masson's trichrome in the different groups, (a) (DMEM +LA7; Masson's trichrome): p (pyknosis), v (vacuoles), bv (congestion), (b) (16h-SFS +LA7; Masson's trichrome): p (pyknosis), f (fibrosis), b (congestion in and around the central vein, (c) (16h-SFS; H&E): i (inflammation), bv (hyperemia), (d) (16h-SFS; Masson's trichrome):, (e) (Normal saline; H&E): without damage, (f) (Normal saline; Masson's trichrome): without damage.
- DMEM +LA7; Masson's trichrome p (pyknosis), v (vacuoles), bv (
- FIG. 21 Histopathology of the lung stained with H&E and Masson's trichrome in the different groups, (a) (DMEM+La7; H&E): at (alveolar wall thickening), fc (foam cell), ia (inflammation of alveolar wall), ba (congestion in alveolar vessels), (b) (16h-SFS; H&E): ta (thickening of alveolar wall), bv (venous congestion), iv (sever inflammation around the vein), (c) (normal saline +LA7; H&E): at (alveolar wall thickening), i (inflammation), dbc (degeneration of bronchial wall), ibc (inflammatory cells in bronchial secretion), (d) (normal saline +LA7; Masson's
- Fig. 22 Blood biochemical and cellular alterations in the different groups after 2 months treatment with indicated solutions. The different hematological and biochemical characteristics measured, the glucose, percentage of eosinophil and triglyceride had significant differences among groups. In comparison to vehicle medium (DMEM), 16h-SFS solution was able to increase glucose level in LA7 injected rats. The different letters show that there was significant difference between groups, with p ⁇ 0.05 was considered as significant.
- DMEM vehicle medium
- FIG. 23 Effects of different fractions of 16-SFS solution on MCF-7 cells survival.
- MCF-7 cells human breast cancer cell line
- viability was measured using MTT assay following the cells treatment with DMEM (Dulbecco's Modified Eagle Medium )+5% FBS (fetal bovine serum), R100 ,R100 +FBS , R50 , R50+FBS , R30 , R30+FBS, R3, R3+FBS, DMEM for 24h.
- the cell viability percentage was calculated based on the absorbance ratio obtained for each indicated treatment compared to DMEM+10% FBS control and multiplied by 100 (% of control).
- LA7 cells rat mammary gland cancer stem cells
- MTT assay following the cells treatment with DMEM (Dulbecco's Modified Eagle Medium) +5% FBS (fetal bovine serum), DMEM, R100, R50, R30, R3, R100+FBS, R50+FBS for 24h.
- the cell viability percentage was calculated based on the absorbance ratio obtained for each indicated treatment compared to DMEM+10% FBS control and multiplied by 100 (% of control).
- A The result indicated that R100, R50, R3 inhibited the growth of LA7 cells as negative control (DMEM).
- Figure 25 Reduction in tumor size and Synergistic effect of 16-SFS solution and bone marrow derived mesenchymal cells (BMMCs) in up-regulation of Cxcl9 and CxcllO chemokine genes expression.
- BMMCs bone marrow derived mesenchymal cells
- the size of tumor in these animals was compared to the size of the tumor in rats received BMMCs only (MSC group) and 16-SFS only, as well as compared to the PBS and DMEM groups as the vehicle controls (six rats in each group). As it can be seen, the tumor size was reduced in MSC and 16-SFS group significantly (P ⁇ 0.05) when compared to their related controls, PBS and DMEM respectively. The tumor size was the lowest level in the group received both treatments. (B and C).
- Figure 26 Effects of 96-SPS solution on Spr and Gchl genes expression and lactate production in rat LA7 induced tumors.
- 96-SPS solution was evaluated the expression of two important genes in cells metabolisms, i.e. Spr and Gchlin those cells.
- Spr gene expression was significantly down-regulated in 96-SPS treated tumors compared to RPMI and normal saline controls (P ⁇ 0.01 and P ⁇ 0.05 respectively).
- B compare to the control the 96-SPS solution was able to down-regulate the Gchl gene expression (P ⁇ 0.001).
- C The 96-SPS treated tumors exhibited a lower level of lactate compared to normal saline control (P ⁇ 0.05). This reduction was not statistically significant in RPMI treated group (P>0.05).
- D A significant reduction in FT ions (increased pH value) was observed in 96-SPS treated group compared to normal saline control (P ⁇ 0.05).
- RPMI group showed no significant changes in pH value (P>0.05). All data was expressed as mean ⁇ SD (standard deviation) and p>0.05 was considered statistically significant. Error bars show SD.
- Figure 27 Sox2 and Oct4 sternness genes expression in 96-SPS treated LA7 induced tumors and controls.
- Figure 28 Histopathologic findings in 96-SPS treated LA7 induced tumors.
- B A tumor isolated from 96-SPS treated rat. After removing the tumor from the body, it was dissected by scalpel in the middle, the pus like liquid was run off and the hallow space remained.
- C Circles indicate the degree of necrosis in different groups of tumors.
- the 96h-SPS treated tumors exhibited the highest extent of necrosis in H and E staining.
- Figure 29 Effects of 16SFS solution on growth of normal and tumor derived cells survival. To estimate the therapeutic index for 16SFS solution we evaluated the effects of this solution on the viability of MCF-
- Example 1 Method of production of the mixture with human neonatal fibroblasts
- Fibroblasts were isolated from fresh foreskin of children (1 to 1.5 months old) by enzymatic method using dispase and collagenase enzymes (Pandamooz et al., 2012), and cultured in Dulbecco's modified eagle's medium (DMEM, Biowest, France), supplemented with 10% fetal bovine serum (FBS, Sigma, Germany), 100 pg/mL streptomycin and 100 lU/mL Penicillin. The cells were incubated at 37 e C with 5% C02 saturation, and were sub-cultured after reaching 70% confluency. The cells have been sub-cultured for fourteen times until their growth was severely slowed down.
- DMEM Dulbecco's modified eagle's medium
- FBS fetal bovine serum
- Penicillin 100 pg/mL
- the cells were incubated at 37 e C with 5% C02 saturation, and were sub-cultured after reaching 70% confluency. The cells have been sub-culture
- those cells culture supernatant was harvested (P14 solution) and stored -20 °C until use.
- Fibroblasts were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. When the cells reached 70% confluency, the cells culture supernatant was removed and washed three times with phosphate buffered saline (PBS). Then, the cells were starved in serum-free DMEM for 16 h at 37 °C. At the end of this period, the starved fibroblasts culture supernatant (16h-SFS) was collected and stored at -20 °C for further analysis.
- PBS phosphate buffered saline
- Example 2 Method of production of the mixture with human PBMCs:
- PBMCs peripheral blood mononuclear cells
- PBMCs-count and viability was determined by trypane staining and using Neubauer Chamber. About 7.5xl0 6 PBMCs were cultured in 75 cm 2 cell culture flasks in glucose- containing serum-free RPMI-1640 with 100 U/mL penicillin and lOOpg/mL streptomycin for 96 hours. Then after, the cells culture supernatant was harvested by centrifugation for 5 minutes at 2000 g.
- each sample (approximately 20 pg protein) were transferred into 2-ml LoBind Eppendorf tubes with pierced lids and frozen for 66 h at -80°C. Subsequently the frozen samples were vacuum dried in a lyophile overnight. The dried samples were each resolved in 50 mI buffer (8 M urea/0.4 M NFI4FIC03, pH 8,5).
- the sample solution was diluted to 2 M urea / 0.1 M NFI4FIC03 with H PLC grade water (VWR). Digest with mass-spec grade trypsin (Serva, porcine) was performed at 37°C overnight. Enzymatic digestion was performed based on the valid version of the SOP H-VED-001 "Enzymatische Spaltung”. The sample was acidified to 1% TFA and 10 mI of the digest was used for the nano-LCESIMS/MS analysis.
- HPLC separation was done using an EASY-nLClOOO (Thermo Scientific) system with the following columns and chromatographic settings:
- the peptides were applied to a C18 column (Acclaim ® PepMap 100 pre column, C18, 3 pm, 2cm x 75 pm Nanoviper, Thermo Scientific) and subsequently separated using an analytical column (EASY-Spray column, 50 cm x 75 pm ID, PepMap C18 2 pm particles, 100 A pore size, Thermo Scientific) by applying a linear gradient (A: 0.1% formic acid in water, B: 0.1% formic acid in 100% ACN) at a flow rate of 280 nl/min.
- A 0.1% formic acid in water
- B 0.1% formic acid in 100% ACN
- composition of the mixture was analyzed as follows:
- LC-ESI-MS/MS data were used for a database search with the software Mascot (Matrix Science) using human sequences from SwissProt database (20 259 sequences).
- Peptide mass tolerance was set to 50 ppm
- fragment mass tolerance was set to 0.6 Da
- a significance threshold p ⁇ 0.05 was used.
- Oxidation at methionine was set as variable modification for the searches.
- Peptides with up to 1 missed cleavage site were searched.
- An ion score cut off of >26 (individual ion score greater than 26 indicate identity or extensive homology) was applied for the peptide identification.
- the detailed results of the database searches are supplied in the appendix, including the proteins identified starting with the highest scores and the peptides identified by MS/MS for each protein.
- the protein significance threshold was set to p ⁇ 0.05 and an ion score cut off of >26 (individual ion score greater than 26 indicate identity or extensive homology) was applied for the peptide identification.
- composition disclosed in the present invention may further comprise one or more proteins selected from the table below.
- proteins disclosed in the above Table are particularly supposed to have a synergic anti cancer effect.
- the table below shows a short list of high score functional candidates expressed under described starvation conditions by neonatal fibroblasts (16SFS mixture). Marked proteins are very important proteins in the list. These possibly more important candidates are selected based on their known/described functions and expression levels in the supernatant (protein score) identified by mass spectroscopy.
- LA7 cells rat mammary gland tumor cells
- DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin/ streptomycin) at 37 °C with 5% C02.
- the cytotoxic effect of the above mentioned supernatants (protein mixture) on LA7 cells were examined using the MTT (3-(4, 5- dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay (Denizot & Lang, 1986).
- the cells (lxlO 4 ) were seeded into each well and treated with different dilution of the fluids as 1/10, 1/2, 1/4, 1/8, 1/16, 1/32 in DMEM solution for 24, 48 and 72 h. Then after, the plate was washed with PBS and incubated with the medium (50 pL) containing 5 mg/mL of MTT dissolved in PBS for 4 h at 37°C. The supernatants were then discarded and 150 pL of Dimethylsulfoxide (DMSO) was added and mixed thoroughly to dissolve dark blue formazan crystals. Then, the optical density (OD) was recorded at 570 nm.
- DMSO Dimethylsulfoxide
- the viability percentage was calculated by the following formula: (OD treated)/ (OD control) xl00, and consequently 50% viability was considered as the half maximal inhibitory concentration (IC 5 o). All experiments were performed in triplicate. As mentioned above, the P14 was prepared from fibroblasts at passage 14. At this passage, some morphological changes such as enlarged cytoplasm with increased levels of granules were appeared. Also the nucleus in those cells was more obviously seen in comparison to the same cells at passage 3 (fig.
- LA7 cells (5xl0 4 ) were cultured in 24-well plate, and the three biological fluids were added after 24 h. Trypsinization was performed after 48 h and cell numbers were determined (fig. 3). Doubling time was calculated for each fluid as the following formula (Roth V. 2006):
- LA7 cells (2.5 xlO 6 ) were cultured in 6-well plate to reach 70% confluency and then incubated with three biological fluids for 24 h. After trypsinization, the cells were stained with Annexin V/phycoeritrin/ 7- Amino-Actinomycin (Annexin V-PE /7-AAD) according to the manufacturer's protocol (BD Bioscience, Germany) and analyzed by flow cytometry (BD FACSCALIBUR, USA) (Fig. 4)
- LA7 cells (lxlO 5 ) were cultured in 12-well plate, scratched vertically using a 100 mI_ micro pipette tip after reaching 100% confluency (Fig. 6). The three biological fluids were added into the plates, and the potential of the migration was evaluated after 24 h and 48h, finally the results were analyzed with image J software (NIH USA).
- stem-loop RT-qPCR assay was used to quantify the gene expression, according to the previously described method (Fattahi, Amirbozorgi, Lotfi, & Amini Navaei, 2018). Briefly, cDNA was synthesized via mRNA specific stem loop-RT primer and RevertAid Reverse Transcriptase (Fermentas, Lithuania). The primers of the four genes were designed using AllelelD 6.0 software (Table 1). RT-qPCR assay was performed with universal Taqman probe using ABI 7300 real-time PCR apparatus (Applied Biosystems, USA). Amplification was programmed as an initial denaturation at 95°C for 5 min, followed by 45 cycles of 95 °C for 30 s and 60 °C for 1 min.
- Inter- and intra-assay coefficients of variation were calculated for Gapdh,C-myc, Sox2, Nanog, and Oct4 genes expression.
- NM_001009178.2 Oct4 Specific forward primer (SEQ ID NO: 35): 225
- CAGCAGCGACTCTGAAGAAGAAC RT-PCR primer SEQ ID NO: 40
- Table 2 Inter- and intra-assay coefficients of variation (CV3 ⁇ 4, for Gapdh, C-mvc, Sox2, Nanoa, and Oct4 using stem-loop (S. D primers
- MCF7 cells (a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman) as well as MCF10A cells (a non-tumorigenic epithelial breast cell line) were cultured in a 96-well culture plate containing DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin/ streptomycin) at 37 °C with 5% C02.
- the cytotoxic effect of the above mentioned supernatants (protein mixture) on these cells were examined using the MTT (3-(4, 5- dimethylthiazolyl-2)-2,5- diphenyltetrazolium bromide) assay (Denizot & Lang, 1986).
- the cells (lxlO 4 ) were seeded into each well and treated with 16SFS solution for 24h. Then after, the plate was washed with PBS and incubated with the medium (50pL) containing 5 mg/mL of MTT dissolved in PBS for 4 h at 37°C. The supernatants were then discarded and 150 pL of Dimethylsulfoxide (DMSO) was added and mixed thoroughly to dissolve dark blue formazan crystals. Then, the optical density (OD) was recorded at 570 nm and the viability was calculated accordingly.
- DMSO Dimethylsulfoxide
- Example 6 In vivo experiment with 16SFS (16 hourse starved fibroblasts)
- Sprague Dawley rats (187 ⁇ 3 g) were obtained from the Laboratory Animal Facility at the Department of Medicine, Medical University of Babol, Iran. The procedure of maintaining the animals was according to the instructions of Ethics Committee of the Babol University of Medical Sciences.
- the rats (5 rats per cage) were divided into 3 groups (A-C), and DMEM (A), 16h-SFS (B), and normal saline (C) were subcutaneously injected into the right mammary gland pad of the animals in each group (300 pL once daily for 6 days). The weight of rats was measured every two days in all groups.
- LA7 cell suspension containing 6 xlO 6 cells in 300 pL phosphate buffered saline (PBS) was injected subcutaneously into the right flank mammary fat pad of each rat through surgery, and then the injected point was stitched. Then, the indicated medium for each group was injected into the rats once daily for 7 days.
- PBS phosphate buffered saline
- the tumor size was daily measured by using calipers, and blood samples were obtained from the tail of the rats for biochemical analysis including glucose, transglutaminase, cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and albumin using commercially available kits (Pars Azmoon Co., Tehran, Iran) and by an Auto-analyzer (Response 910, Dia Sys, Holzheim, Germany).
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- ALP alkaline phosphatase
- albumin albumin
- the stained sections were then evaluated, and images were captured using light microscopy (Olympus BX51, Tokyo, Japan).
- the type of tumor was identified using Ki67 (Dako, Denmark, Clone MIB-1), cytokeratin (Dako, Denmark, Clone AE1/AE3), CD45 (Diagnostic BioSystem, Clone PD7/26+2B11), and Estrogen receptors(ER) markers (Dako, Denmark, Clone 1D5).
- Ki67 DermataTajhiz Azam, Tehran, Iran
- cytokeratin Dako, Denmark, Clone AE1/AE3
- CD45 Diagnostic BioSystem, Clone PD7/26+2B11
- Estrogen receptors(ER) markers Dako, Denmark, Clone 1D5
- the samples were placed in RNA later solution (YektaTajhiz Azam, Tehran, Iran) and stored at -80 °C.
- RT-qPCR assay was used, according to the previously described method. Briefly, cDNA was synthesized via mRNA specific stem loop-RT primer and RevertAid Reverse Transcriptase (Fermentas, Lithuania). The primers of the four genes were designed using AllelelD 6.0 software (Table 3). RT-qPCR assay was performed with universal Taqman probe using ABI 7300 real-time PCR apparatus (Applied Biosystems, USA). Amplification was programmed as an initial denaturation at 95 °C for 5 min, followed by 45 cycles of 95 °C for 30 s and 60 °C for 1 min.
- CAGCAGCGACTCTGAAGAAGAAC RT-PCR primer SEQ ID NO: 50
- Stem-loop sequence is underlined; target specific portion of mRNA is shown with different color.
- the data were expressed as mean ⁇ SD. To examine normality of the data, Kolmogorov Smirnov test was used. For multiple comparisons, One-Way ANOVA along with Tukey test was used. Also, repeated measure ANOVA was used for analyzing data from one group with different variables. The significance level assigned was P ⁇ 0.05. SPSS ver. 24 software (IBM corp., USA) was used for statistical analysis.
- Fig. 12 After 8 days of LA7 injection, the tumors were observed to be explanted (Fig. 12). In 16h-SFS treated animal, the tumor size was remarkably smaller than animals treated with DMEM or normal saline ( Fig.11a and Fig. 12). Flowever, this difference was not statistically significant.
- the tumor histology showed some different alterations in mitosis, necrosis and inflammatory cells infiltration among groups.
- the number of mitotic cells in normal saline group had significant difference with the two other groups (p ⁇ 0.05) (Fig.15b).
- the level of necrosis in 16h-SFS treated tumors was higher than the two other groups.
- the number of mast cells (based on Giemsa staining) in DMEM group, and the level of polymorphonuclear cells (PMNs) in normal saline group were slightly higher than that in the two other groups.
- the markers used Karlin, AE1/AE3, CD45, and ER
- Example 7 Systemic effects of starved fibroblast culture supernatant on immunosuppressed rats treated with cancer stem cells (LA7)
- Tumorigenesis is a (multi) complex biological process in which different types of cells contribute in an orchestral manner.
- This cellular network consists of malignant cells, endothelial cells, immune cells, and fibroblasts, among of which non-tumor cells play different roles but orchestra to angiogenesis and tumor metastasis, and fibroblasts of stromal cells play an important role in angiogenesis (cancer-associated fibroblast).
- fibroblasts have secretory phenotype releasing different compounds into the extracellular matrix, each of which can have important roles at all stages of cancer progression, wound healing and regeneration.
- Cancer stem cells are among a few cancer cells surviving during different steps of metastasis and have high potential in initiating and promoting metastasis.
- LA7 with especially expressed markers shows high tumorigenicity characteristics and is considered as a reliable model for studying the development and differentiation of breast cancer.
- Research about metastatic breast cancer usually needs the methods for transduction and the evolution of tumor in animal models. Different methods have been introduced in this case, and theinduction of breast cancer tumor by injection of LA7 cells cultured in the medium is a relatively new method applied in cancer research in vivo.
- angiogenesis plays a pivotal role in tumor survival and promotion. Indeed, serum starvation nearly is considered as a model for a biological study on tumor.
- the 16SFS solution induces a rate of proliferation in fibroblasts after return to normal culture system (with serum). We expect that these proteins should have some positive effect through angiogenesis on tumor development or progression and spreading (metastasis).
- LA7 as a model to examine this hypothesis. Because LA7 originates from Sprague Dawley rat, we initially used dexamethasone (3mg/kg) to suppress the immune system and to implant and progress tumor to different organs like liver, intestine, and lung.
- mice Thirty female Wistar rats (8-10 weeks old, 244 ⁇ 4.5 g) were provided from the Laboratory Animal Facility at the Department of Medicine, University of Babol, Iran. They were maintained at 25 ⁇ 3 °C with relative humidity, a cycle of 12 h-light and 12 h-dark, and standard food pellets and tap water. The rats were divided into 6 groups (A-F) and after acclimation (5 rats per cage), dexamethasone was intraperitoneally injected to the animals in all groups (3 mg/kg once daily for 6 days) except group F similarly receiving normal saline (table 1). The weight of rats was measured every 2 days.
- LA7 rat mammary gland tumor cells
- DMEM Dulbecco's modified eagle's medium
- FBS fetal bovine serum
- All flasks containing these cells were incubated at 37 e C with 5% C02 saturation. After reaching 90% confluence, the supernatant of cultured LA7 cells were removed from the medium, and the cells were washed with PBS.
- the cells were detached from the culture flask by adding trypsin (EDTA), put into a falcon tube, centrifuged at 400g for 5 min at 4 °C and washed with PBS. The cells were then counted using a hemocytometer.
- EDTA trypsin
- 16 hours-starved fibroblast cell culture supernatant The isolation of fibroblasts from the fresh foreskin of children (1 to 1.5 months old) was carried out by an enzymatic method using dispase and collagenase enzymes (Pandamooz et a I., 2012). The isolated fibroblasts were incubated in a complete culture medium. After reaching 80% confluence, the fibroblasts were cultured in free-serum DMEM, and the supernatant was collected after 16 hours (16h - SFS) based on our previous report (Golpour, et al. 2014).
- LA7 cell suspensions containing 5x106 cells in 300 mI_ PBS were injected subcutaneously into the right flank mammary fat pad of each rat from group A (DMEM+LA7), C (16h-SFS+ LA7) and E (Normal saline+IA7) using insulin syringe and a 21-gauge needle; while other groups received DMEM (group B), 16h-SFS (group D).
- group B group A
- 16h-SFS group D
- Five rats which were considered as dexamethasone treated control received only normal saline for indicated days (group F).
- the special medium for each group including DMEM (A and B), 16h-SFS (C and D) and normal saline (E and F), were injected into the rats once daily for 14 days (Table 5).
- Table 5 Experimental design and arrangement of injections Histological and biochemical examinations: After 53 days of LA7 cell injection (60th day), the rats were dissected and the liver, small intestine, and lung were removed, fixed in formalin and embedded in paraffin. The blocks were sectioned (5 pm), and stained with Hematoxylin & Eosin (H & E) or Masson's trichrome. The stained sections were then evaluated, and images were captured using light microscopy (Olympus BX51, Tokyo, Japan). For biochemical examinations, the blood samples were taken from the tail of the rats after 60 days, centrifuged at 400 g for 10 min and obtained serum was stored at -80 °C for further use.
- Histological findings We evaluated the histopathological changes in the lung and liver qualitatively and semi-quantitatively, and determined some hematological indices implying the bone marrow function.
- Example 8 Further discovering the potential proteins in the 16-SFS solution with anti-cancer activity
- the 16-SFS solution was initially fractionated and analyzed through the MTT assay to determine the effects of different fractions on various cell lines (including rat LA7 cells and MCF-7; a human breast cancer cell line).
- the 16- SFS solution was sequentially fractionated using amicon ultra-filtration centrifugal devices with different cutoffs (molecular weights; cutoff 3K, 30K, 50K and 100k).
- the concentrated portions were collected and named R (e.g. R50; which means fraction with molecules bigger than 50 KDa).
- the flow through was subjected to the next filtration device with smaller size.
- the R100, R50, R30and R3 obtained from 16-SFS fractionation were used for further analysis.
- the R100 fraction shows positive effect on MCF-7human cancer cells.
- the R50 fraction remarkably reduces the cells viability but in presence of serum lost its effect.
- the R30 and R3 fractions strongly reduce the cell growth and keep this property even when the serum was added to the fractions.
- those fractions are candidates for further analysis of their anti- cancer effects compare to the R100 fraction which shows pro-tumor activities. Inhibition of these proteins by specific antibodies or molecular based technologies (e.g. RNA silencing or gene therapy) in cancer cells may be beneficial in cancer therapy.
- LC-ESI-mass spectrometry analysis of R3, R30, R50 and R100 fractions Using the nano-LC-ESI-MS/MS analysis of the whole 16-SFS solution and above mentioned fractions (SUPPLEMENTRAY) as well as according to the experimental analysis, we could propose the list of the following candidates having anti-cancer effect: Thrombospondin-1, Metalloproteinase inhibitor 1, Pentraxin-related protein PTX3, Follistatin-related protein 1, Fibulin-1, Pigment epithelium-derived factor, Inter-alpha-trypsin inhibitor heavy chain H2, SPARC, Insulin-like growth factor-binding protein 6, Metalloproteinase inhibitor 2, Insulin-like growth factor-binding protein 4, Follistatin, Liprin-beta-2 (Fragment), Uveal autoantigen with coiled-coil domains and ankyrin repeats, Transgelin-2 (Fragment), Stanniocalcin-2 (Fragment), Insulin-like growth factor-bind
- Example 9 Co-administration of 16-SFS solution and bone marrow derived mesenchymal cells (BMMCs) enhances the inhibition of LA7 derived tumor development in rat in association with CXCL9, CXC10 chemokines gene expression
- 16-SFS solution revealed the existence of stromal-cell derived factor 1(SDF1) in this solution
- SDF1 stromal-cell derived factor 1
- BMMCs were also able to decrease the size of the tumors when compared to the PBS and DMEM control groups (p ⁇ 0.01 and p ⁇ 0.001 respectively). Interestingly, in the in vitro study this was able to inhibit directly the LA7 proliferation (Figure 25D).
- Example 10 96-SPS down-regulated the Spr and Gchl genes expression and reduced lactate levels in LA7-induced tumors
- Lactate is one of the metabolic product described originally as Warburg effect which is a common metabolic reprogramming factor in solid tumors microenvironments.
- the 96-SPS treated tumors exhibited a lower level of this ions compared to normal saline control (p ⁇ 0.05). This reduction was not statistically significant in RPMI treated group (p>0.05).
- Figure 26C Interestingly, a significant reduction in FT ions (increased pH value) was also observed in this group compared to normal saline control (p ⁇ 0.05). RPMI group showed no significant changes (p>0.05).
- the therapeutic index formula as the ratio of inhibition rate for malignant cells, (%99 for MCF7 in this experiment)/ratio of inhibition for healthy cells namely, (%11 in this study MCF10), the calculated therapeutic index of 16SFS solution is 9. Even in presence of serum this index is not changed remarkably.
- dexamethasone had a significant effect on the weight of rat, there is no report to show histological damages of dexamethasone in the liver, lung, and intestine of rat after intraperitoneal exposure, and some studies introduced dexamethasone as a therapeutic and protective agent. Flowever, Kumar et al. showed that dexamethasone could cause hepatic steatosis in the rat. Nevertheless, the results of the Examples in the present application showed that pyknosis occurred in the liver cells of all groups treated with dexamethasone. Pyknosis shows stress condition (e.g., oxidative stress) and occurs in dying cells due to nuclear condensation.
- stress condition e.g., oxidative stress
- fibrosis is the disruption of extracellular matrix homeostasis due to the excessive production of some components especially collagen Tumor cells like LA7 can disrupt the homeostasis through activation of fibroblasts and some immune cells resulting in fibrosis; and this event leads to enhancing the potential of tumor cells to be colonized.
- Foam cells are common histological damages in lung fibrosis and, however, our results did not show any relationship between fibrosis and foam cell formation, probably due to interactions of the other factors. Foam cell formation may be one reason for alteration of triglyceride concentration.
- SEQ ID NO 3 Metalloproteinase inhibitor 2
- SEQ ID NO 4 Insulin-like growth factor-binding protein 4
- SEQ ID NO 5 Uveal autoantigen with coiled-coil domains and ankyrin repeats
- MDEDVQEALLQIIQMRQGLVC SEQ ID NO 6 Insulin-like growth factor-binding protein 5
- SEQ ID NO 9 Metalloproteinase inhibitor 1
- SEQ ID NO 10 Pentraxin-related protein PTX3
- SEQ ID NO 12 Follistatin-related protein 1
- SEQ ID NO 15 Inter-alpha-trypsin inhibitor heavy chain H2
- SEQ ID NO 17 Growth-regulated alpha protein
- SEQ ID NO 18 Insulin-like growth factor-binding protein 6
- SEQ ID NO 22 Tumor necrosis factor-inducible gene 6 protein
- SEQ ID NO 23 Transforming growth factor-beta-induced protein ig-h3
- SEQ ID NO 27 Stanniocalcin-2 (Fragment)
- SEQ ID NO 29 Latent-transforming growth factor beta-binding protein 2
- SEQ ID NO 30 Insulin-like growth factor-binding protein 7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition comprenant : une protéine de facteur dérivé de l'épithélium pigmentaire ayant une séquence de SEQ ID NO : 1 ou un fragment de celle-ci, la protéine thrombospondine-2 ayant une séquence de SEQ ID NO : 2 ou un fragment de celle-ci, et/ou la protéine d'inhibiteur de métalloprotéinase 2 ayant une séquence de SEQ ID NO : 3 ou un fragment de celle-ci, et/ou la protéine de liaison au facteur de croissance analogue à l'insuline 4 ayant une séquence de SEQ ID NO : 4 ou un fragment de celle-ci, une composition pharmaceutique la comprenant, et un procédé de préparation de celle-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19218585 | 2019-12-20 | ||
EP19218585.8 | 2019-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021123320A1 true WO2021123320A1 (fr) | 2021-06-24 |
Family
ID=69061065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/087239 WO2021123320A1 (fr) | 2019-12-20 | 2020-12-18 | Composition et son utilisation pour une thérapie universelle contre les cellules tumorales |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021123320A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011103472A1 (fr) * | 2010-02-18 | 2011-08-25 | Osiris Therapeutics, Inc. | Procédés de fabrication de produits thérapeutiques comprenant des dispersions placentaires vitalisées |
WO2015171142A1 (fr) * | 2014-05-07 | 2015-11-12 | Osiris Therapeutics, Inc. | Compositions placentaires thérapeutiques, procédés de fabrication et méthodes d'utilisation |
WO2020210248A1 (fr) * | 2019-04-09 | 2020-10-15 | Combangio, Inc. | Procédés de fabrication et d'utilisation d'un sécrétome dérivé de cellules souches mésenchymateuses |
-
2020
- 2020-12-18 WO PCT/EP2020/087239 patent/WO2021123320A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011103472A1 (fr) * | 2010-02-18 | 2011-08-25 | Osiris Therapeutics, Inc. | Procédés de fabrication de produits thérapeutiques comprenant des dispersions placentaires vitalisées |
WO2015171142A1 (fr) * | 2014-05-07 | 2015-11-12 | Osiris Therapeutics, Inc. | Compositions placentaires thérapeutiques, procédés de fabrication et méthodes d'utilisation |
WO2020210248A1 (fr) * | 2019-04-09 | 2020-10-15 | Combangio, Inc. | Procédés de fabrication et d'utilisation d'un sécrétome dérivé de cellules souches mésenchymateuses |
Non-Patent Citations (4)
Title |
---|
BARRON GEMMA A. ET AL: "Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation", ONCOLOGY REPORTS, vol. 38, no. 3, 1 March 2017 (2017-03-01), pages 1886 - 1894, XP055797619, ISSN: 1021-335X, DOI: 10.3892/or.2017.5803 * |
NYBERG PIA ET AL: "Endogenous Inhibitors of Angiogenesis", CANCER RESEARCH, vol. 65, no. 10, 15 May 2005 (2005-05-15), US, pages 3967 - 3979, XP055796917, ISSN: 0008-5472, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/canres/65/10/3967.full.pdf> DOI: 10.1158/0008-5472.CAN-04-2427 * |
POLLINA ELIZABETH A. ET AL: "Regulating the angiogenic balance in tissues: A potential role for the proliferative state of fibroblasts", CELL CYCLE, vol. 7, no. 13, 1 July 2008 (2008-07-01), US, pages 2056 - 2070, XP055797364, ISSN: 1538-4101, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.4161/cc.7.13.6240?needAccess=true> DOI: 10.4161/cc.7.13.6240 * |
SUN JING-YUAN ET AL: "Knockdown of UACA inhibits proliferation and invasion and promotes senescence of hepatocellular carcinoma cells", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 11, no. 9, 1 January 2018 (2018-01-01), US, pages 4666 - 4675, XP055797212, ISSN: 1936-2625, Retrieved from the Internet <URL:http://www.ijcep.com/files/ijcep0080997.pdf> * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meng et al. | Functional role of cellular senescence in biliary injury | |
Bourlier et al. | TGFbeta family members are key mediators in the induction of myofibroblast phenotype of human adipose tissue progenitor cells by macrophages | |
Villanueva et al. | Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure | |
US10293001B2 (en) | Compositions and methods for restoring or rejuvenating stem/progenitor cell function | |
Bitar et al. | Caveolin-1/PTRF upregulation constitutes a mechanism for mediating p53-induced cellular senescence: implications for evidence-based therapy of delayed wound healing in diabetes | |
Gao et al. | Overexpression of Csx/Nkx2. 5 and GATA-4 enhances the efficacy of mesenchymal stem cell transplantation after myocardial infarction | |
Huang et al. | EPC-derived exosomal miR-1246 and miR-1290 regulate phenotypic changes of fibroblasts to endothelial cells to exert protective effects on myocardial infarction by targeting ELF5 and SP1 | |
Brunt et al. | Role of WNT/β-catenin signaling in rejuvenating myogenic differentiation of aged mesenchymal stem cells from cardiac patients | |
Abbate et al. | Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury | |
Zhou et al. | Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy | |
Li et al. | Circular RNA 0001273 in exosomes derived from human umbilical cord mesenchymal stem cells (UMSCs) in myocardial infarction. | |
Zhao et al. | Role of tumor necrosis factor-α in epithelial-to-mesenchymal transition in transplanted kidney cells in recipients with chronic allograft dysfunction | |
Wang et al. | Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse | |
Zhou et al. | Reduction of fibrosis in dibutyltin dichloride–induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly | |
Wang et al. | Loss of legumain induces premature senescence and mediates aging‐related renal fibrosis | |
Ren et al. | Platelet-derived growth factor-BB and epidermal growth factor promote dairy goat spermatogonial stem cells proliferation via Ras/ERK1/2 signaling pathway | |
Pandya Thakkar et al. | Elevated H3K4me3 through MLL2-WDR82 upon hyperglycemia causes jagged ligand dependent notch activation to interplay with differentiation state of endothelial cells | |
EP4079313A1 (fr) | Composition pour la prévention ou le traitement de maladies rénales, comprenant des exosomes dérivés de cellules précurseurs de cellules souches mésenchymateuses dérivées de cellules souches pluripotentes induites | |
Yang et al. | Inhibition of RIP3 increased ADSC viability under OGD and modified the competency of adipogenesis, angiogenesis, and inflammation regulation | |
Nassar et al. | Sodium hydrosulfide and bone marrow derived mesenchymal stem cells combined therapy for bleomycin induced pulmonary fibrosis in rats: Implication of micro RNA-21 and Lnc GAS5 | |
WO2021123320A1 (fr) | Composition et son utilisation pour une thérapie universelle contre les cellules tumorales | |
Van Langendonckt et al. | Gene expression in human ovarian tissue after xenografting | |
Zhou et al. | RETRACTED: Curcumin Blunts IL-6 Dependent Endothelial‐to‐Mesenchymal Transition to Alleviate Renal Allograft Fibrosis Through Autophagy Activation | |
Gao et al. | Hic-5 deficiency attenuates hepatic ischemia reperfusion injury through TLR4/NF-κB signaling pathways | |
Didar et al. | Influence of mesenchymal stem cells and royal jelly on kidney damage triggered by ischemia-reperfusion injury: comparison with ischemic preconditioning in an animal model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20835811 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20835811 Country of ref document: EP Kind code of ref document: A1 |